Drug intelligence / Profile preview

GBP3 siRNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral, Intravenous, Parenteral
01

Overview

GBP3 siRNA is a small interfering RNA designed to silence the expression of Guanylate-binding protein 3 (GBP3). GBP3 is a member of the interferon-inducible GTPase family and has been implicated in the progression of various cancers, most notably glioblastoma multiforme and oral squamous cell carcinoma, where it often promotes cell proliferation, migration, and resistance to apoptosis. By utilizing the RNA interference (RNAi) pathway, GBP3 siRNA facilitates the sequence-specific degradation of GBP3 mRNA, thereby reducing protein levels and inhibiting the downstream signaling pathways associated with tumor growth. While currently utilized primarily as a research tool in preclinical oncology and immunology studies, it represents a potential therapeutic strategy for targeting GBP3-overexpressing malignancies.

Other names
siRNA targeting GBP3GBP3-siRNAGBP-3-siRNAGBP 3-siRNAGuanylate-binding protein 3 siRNA
02

Targets

GBP (Glucan-binding protein)

Beyond the preview

Go deeper on GBP3 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GBP3 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call